HER2/neu expression in oral squamous cell carcinoma

Asian Journal of Oral and Maxillofacial Surgery

Volumn 16, Issue 3, 2004, Pages 172-176

  Shintani, Satoru ^a   Nakahara, Yuuji ^a   Li, Chunnan ^a   Mihara, Mariko ^a   Nakashiro, Koh Ichi ^a   Hamakawa, Hiroyuki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HER2 neu; Immunohistochemistry; Squamous cell carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ONCOGENE NEU; SQUAMOUS CELL CARCINOMA;

EID: 7944226120     PISSN: 09156992     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0915-6992(04)80028-1     Document Type: Article

References (26)

1. Popescu NC, King CR, Kraus NH. Localization of the erbB-2 gene on normal and rearranged chromosomes 17 to bands of q 12-21.32. Genomics 1989; 4:362-366.
2. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of human c-erbB-2 gene: a 185-kDa glycoprotein with tyrosine-kinase activity. Science 1986;232:1644-1646.
3. Yamamoto T, Ikawa S, Akiyama T. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319:230-234.
4. Press MF, Cordon-Card C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.
5. Venter DJ, Tuzi, NL Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncogene protein in human breast carcinomas; immunohistochemical assessment correlates with gene amplification. Lancet 1987;11:69-72.
6. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL, Hung MC. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9.
7. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5: 4164-4174.
8. Baselga J, Tripathy D, Mendelsohn J. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14: 737-744.
9. Pegram MD, Lipton A, Hayes DF. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized and p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
10. Cobleigh MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
11. Kearsley JH, Leonard JH, Walsh MD, Wright GR. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991;23:189-194.
12. Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ. Expression of c-erbB2 gene in human head and neck carcinoma. Anticancer Res 1992;12:2273-2276.
13. Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM. c-erbB2 Expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992;12:613-620.
14. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 1992;65: 215-220.
15. Irish J, Bernstein A. Oncogenes in head and neck cancer. Laryngoscope 1993;103:42-52.
16. Rodrigo JP, Ramos S, Lazo PS, Alvarez I, Suarez C. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur J Cancer Part A 1996;32:2004-2010.
17. Werkmeister R, Brandt B, Joos U. The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. Am J Surg 1996;172:681-683.
18. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997;17:4539-4546.
19. Ibrahim SO, Lillehaug JR, Johannessen AC, Liavaag PG, Nilsen R, Vasstrand EN. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. Oral Oncol 1999;35:302-313.
20. Werkmeister R, Brandt B, Joos U. Clinical relevance of erbB-1 and-2 oncogenes in oral carcinomas. Oral Oncol 2000;36:100-105.
21. Sobin LH, Fleming ID. TNM Classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
22. Espinoza F, Anguiano A. The HercepTest assay: another perspective. J Clin Oncol 1999;17: 2293-2294.
23. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999;26:108-116.
24. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
25. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
26. Cobleigh MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.